MMV019662 TFA is a PfNCR1 inhibitor and antimalarial agent. MMV019662 TFA reduces gametocytemia levels of Plasmodium falciparum. MMV019662 TFA is applicable to malaria-related research [1] [2].
In Vitro, MMV019662 (3× EC90; 13 days) TFA significantly reduces the total gametocytaemia level of blood-stage gametocytes of Plasmodium falciparum[1]. MMV019662 (72 h) TFA inhibits the growth of the asexual erythrocytic stage of P. falciparum (Plasmodium falciparum) with an EC50 of 1.18 μM[1]. MMV019662 (0-100 μM) TFA does not thermostabilize purified PfNCR1[1].
References:
[1]. Kohling A, et al. Targeting ligand binding sites in Plasmodium falciparum NCR1 enables antimalarial drug discovery. bioRxiv, 2025: 2025.11. 11.687791.
[2]. Zhang Z, et al. The Plasmodium falciparum NCR1 membrane protein is a novel antimalarial target that exports cholesterol to maintain membrane homeostasis. bioRxiv, 2024: 2024.09. 30.615907.
In Vitro, MMV019662 (3× EC90; 13 days) TFA significantly reduces the total gametocytaemia level of blood-stage gametocytes of Plasmodium falciparum[1]. MMV019662 (72 h) TFA inhibits the growth of the asexual erythrocytic stage of P. falciparum (Plasmodium falciparum) with an EC50 of 1.18 μM[1]. MMV019662 (0-100 μM) TFA does not thermostabilize purified PfNCR1[1].
References:
[1]. Kohling A, et al. Targeting ligand binding sites in Plasmodium falciparum NCR1 enables antimalarial drug discovery. bioRxiv, 2025: 2025.11. 11.687791.
[2]. Zhang Z, et al. The Plasmodium falciparum NCR1 membrane protein is a novel antimalarial target that exports cholesterol to maintain membrane homeostasis. bioRxiv, 2024: 2024.09. 30.615907.